Shares of ImmuPharma plc (LON:IMM – Get Free Report) were down 3.4% on Tuesday . The company traded as low as GBX 8.20 and last traded at GBX 8.98. Approximately 10,016,895 shares traded hands during mid-day trading, an increase of 149% from the average daily volume of 4,020,944 shares. The stock had previously closed at GBX 9.30.
ImmuPharma Price Performance
The firm has a market cap of £38.71 million, a P/E ratio of -8.65 and a beta of 1.53. The company has a fifty day moving average of GBX 6.60 and a 200-day moving average of GBX 7.59.
About ImmuPharma
ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.
Further Reading
- Five stocks we like better than ImmuPharma
- Your Bank Account Is No Longer Safe
- Nvidia CEO Issues Bold Tesla Call
- NEW LAW: Congress Approves Setup For Digital Dollar?
- Buy this Gold Stock Before May 2026
- What a Former CIA Agent Knows About the Coming Collapse
Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.
